✦ LIBER ✦

Phase II study of amonafide in patients with recurrent glioma

✍ Scribed by Ralph Levitt; Jan C. Buckner; Terrence L. Cascino; Patrick A. Burch; Roscoe F. Morton; Mark W. Westberg; Richard M. Goldberg; James G. Gallagher; Judith R. O'Fallon; Bernd W. Scheithauer

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 932 KB
Volume: 23
Category: Article
ISSN: 0167-594X
DOI: 10.1007/bf01058464

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of amonafide in advanced

Phase II study of amonafide in advanced and recurrent sarcoma patients

✍ Raymond P. Perez; Sherri L. Nash; Robert F. Ozols; Robert L. Comis; Peter J. O'D 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 177 KB

Phase II study of amonafide in gastric a

Phase II study of amonafide in gastric adenocarcinoma

✍ Michael R. Mullane; Richard L. Schilsky; Rosemary B. Carroll; James L. Wade; Lar 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 285 KB

Phase II study of amonafide in advanced

Phase II study of amonafide in advanced pancreatic adenocarcinoma

✍ Kaye Linke; Richard Pazdur; James L. Abbruzzese; Jaffer A. Ajani; Rodger Winn; J 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 262 KB

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m 2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Be

Phase II study of amonafide in advanced

Phase II study of amonafide in advanced breast cancer

✍ W. Scheithauer; C. Dittrich; G. Kornek; K. Haider; W. Linkesch; H. Gisslinger; D 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 525 KB

Phase II study of ifosfamide with mesna

Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma

✍ T. E. Elliott; J. C. Buckner; T. L. Cascino; R. Levitt; J. R. O'Fallon; B. W. Sc 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 318 KB

Sixteen patients who developed CT or MRI scan evidence of recurrent diffuse astrocytoma after radiation therapy and nitrosourea-containing chemotherapy received ifosfamide (2500 mg/m2/day for 3 consecutive days) and mesna (500mg/m2/dose, 5 doses/day for 3 consecutive days). Toxicity consisted primar

Phase II study of ecteinascidin 743 in h

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

✍ Caroline Laverdiere; E. Anders Kolb; Jeffrey G. Supko; Richard Gorlick; Paul A. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

## Abstract ## BACKGROUND Recurrent osteosarcoma is a drug‐resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET‐743) as a salvage therapy in these patients. ## METHODS Patients with recurrent osteosarcoma who had re